Oncology chain HCG to buy majority stake in Kenyan firm

Bangalore-based Healthcare Global Enterprises Ltd (HCG) has agreed to purchase a majority stake in a cancer-care centre in Kenya in its first overseas acquisition.
HCG will buy a 93.66% stake in Nairobi-based Cancer Care Kenya Ltd for 93.15 million Kenyan shillings (about $905,000) in cash, the Indian company said in a stock-exchange filing. HCG will acquire the stake through step-down subsidiary HealthCare Global (Kenya) Pvt Ltd.
HCG added that it has also signed a pact with Nairobi-based MP Shah Hospital and Cancer Care Kenya’s promoters to subscribe to shares of the target company. After this pact is concluded, HCG will have a 77.5% stake in Cancer Care Kenya while MP Shah Hospital will have 10%. The target company’s promoters will have the remaining 12.5% stake.
“We expect to bridge the demand-supply gap existing in the cancer care space in Kenya, where patients have to travel out of the country for availing cancer care services due to inadequate treatment facilities in Kenya,” HCG said.
The transaction is subject to approval from the Competition Authority of Kenya and is likely to be completed by the end of June, the company said.
This is the first major takeover deal by HCG in more than three years. In 2013, HCG had acquired a 50% stake in Bengaluru-based fertility care provider Bangalore Assisted Conception Centre Pvt Ltd.
HCG is backed by PremjiInvest, the investment arm of Wipro Ltd chairman Azim Premji, and World Bank arm International Finance Corporation. Earlier this month, PremjiInvest sold a 2.54% stake in the company.
HCG, which has 17 cancer treatment centres across India, made its stock market debut exactly one year ago on a rather disappointing note with its shares plunging 21.6% at the end of first day’s trade.
Source: https://www.vccircle.com/oncology-chain-hcg-to-buy-majority-stake-in-kenyan-firm/ 

Comments

  1. shaikhApril 11, 2021 at 3:36 PM

    онкология это When your website or blog goes live for the first time, it is exciting. That is until you realize no one but you and your.

    ReplyDelete

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more